培门冬酶联合调强适形放疗治疗早期鼻腔NK／T细胞淋巴瘤20例效果观察  

Efficacy observation of pegaspargase combined with intensity modulated conformal radiotherapy in the treatment of 20 patients with early-stage nasal NK/T call lymphoma

作　　者：刘小梅 黄韵红[2] 胡云飞[2] 宋扬[2] 甘家应[2] 

机构地区：[1]九江市第三人民医院肿瘤科,332000 [2]贵州省肿瘤医院淋巴瘤科,贵阳550005

出　　处：《白血病．淋巴瘤》2016年第3期186-188,共3页Journal of Leukemia & Lymphoma

摘　　要：目的观察培门冬酶联合调强适形放疗（IMRT）治疗Ⅰ～Ⅱ期鼻腔NK／T细胞淋巴瘤的效果及患者不良反应。方法回顾性分析2011年1月至2013年9月20例原发鼻腔NK／T细胞淋巴瘤患者的临床资料，其中，男性14例，女性6例；中位年龄41岁（16～66岁）。采用以培门冬酶为主的POD方案化疗联合IMRT。结果20例患者完全缓解10例，部分缓解7例，稳定1例，进展2例。不良反应多为Ⅰ～Ⅱ度，可耐受。结论培门冬酶联合IMRT同步治疗I～Ⅱ期鼻腔NK／T细胞淋巴瘤疗效好，不良反应轻。Objective To study the clinical characteristics, diagnosis, treatment and prognosis of primary pulmonary peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Methods Two cases of primary pulmonary PTCL-NOS were studied and relevant literature were reviewed. Results Case 1 diagnosed as primary pulmonary PTCL-NOS was a 44 years old woman and disease progressed after GLD (Gem+L-OHP+ DXM) chemotherapy regimen. At last, the patient died of respiratory failure after one month. Case 2 diagnosed as primary pulmonary PTCL-NOS was a 46 years old man and reach partial response after CHOP regimen, and still alive now.Conclusion Primary pulmonary PTCL-NOS is very rare. It is easy to be misdiagnosed due to non-specific clinical and imaging manifestations. Acquiring enough tissue specimens for pathologic examination is the key to a definitive diagnosis. At present, there is no standard chemotherapy regimen for these patients, the prognosis is relatively poor.

关 键 词：淋巴瘤 鼻腔NK/T细胞 培门冬酶 放射疗法 调强适形 

分 类 号：R739.62[医药卫生—肿瘤]